Stock analysts at Aegis started coverage on shares of CombiMatrix Corp. (NASDAQ:CBMX) in a note issued to investors on Thursday. The firm set a “buy” rating and a $5.00 price target on the stock. Aegis’ price target would suggest a potential upside of 66.67% from the company’s previous close.
CombiMatrix Corp. (NASDAQ:CBMX) opened at 3.00 on Thursday. CombiMatrix Corp. has a 12-month low of $2.62 and a 12-month high of $18.15. The stock’s 50 day moving average is $3.01 and its 200 day moving average is $3.21. The stock’s market capitalization is $7.13 million.
CombiMatrix Corp. (NASDAQ:CBMX) last issued its quarterly earnings results on Wednesday, August 3rd. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.27) by $0.62. CombiMatrix Corp. had a negative net margin of 52.71% and a negative return on equity of 80.98%. Equities analysts predict that CombiMatrix Corp. will post ($2.70) earnings per share for the current fiscal year.
About CombiMatrix Corp.
CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies.
Receive News & Ratings for CombiMatrix Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CombiMatrix Corp. and related companies with MarketBeat.com's FREE daily email newsletter.